Genetic Dyslipidemias: Familial Hypercholesterolemia and Beyond
This activity is supported by educational funding provided by Alexion Pharmaceuticals and Amryt Pharma DAC.
Click Here to Manage Email Alerts
Overview
Launch Date: December 2, 2021
Expiration Date: December 2, 2022
Provider Statement
Join the NLA to solve the mystery of genetic dyslipidemias. After reviewing a patient profile, you will make your diagnosis and receive real-time critiques from our lipid specialists.
Support Statement
This activity is supported by educational funding provided by Alexion Pharmaceuticals and Amryt Pharma DAC.
Target Audience
This activity is intended for cardiologists, primary care physicians, diabetologists and endocrinologists, nurses, pharmacists, and other healthcare professionals involved in managing patient with dyslipidemia.
Learning Objectives
At the conclusion of this activity, all participants should be able to:
- Demonstrate knowledge of the mechanisms and manifestations of HoFH, HeFH, Sitosterolemia, and LAL-D.
- Counsel patients with genetic dyslipidemias on comprehensive management plans.
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
Faculty
Don P. Wilson, MD, FNLA
Division of Endocrinology
Director, Pediatric CV Health and Risk Prevention Clinic
Cook Children’s Medical Center, Fort Worth, TX
Karen Aspry, MD, FNLA
Director, Lipid Clinic & CVD Prevention Program
Department of Medicine, Warren Alpert Medical School, Brown University
East Greenwich, RI
P. Barton Duell, MD, FNLA
Department of Medicine, Oregon Health and Science University
Portland, OR
Reviewer
Pamela Papp, APRN, CLS, FNLA
Saint Charles, IL
Accreditation
CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Credit Designation Statement
The National Lipid Association designates this internet live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
Pharmacist Accreditation Statement
Universal Activity Number – JA0007192-0000-21-040-H01-P (Application)
This Activity has been approved for 1.50 contact hour(s) (.150 CEUs) of the Accreditation Council for Pharmacy Education.
Nursing
The maximum number of hours awarded for this CE activity is 1.5 contact hours.
How to Participate in this Activity and Obtain CME Credit
Statements of credit will be awarded based on the participant’s review of the activity content, a passing score of 75% on the activity assessment, and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form. The deadline to claim credit is April 30, 2022. Questions related to this content should be sent to cme@lipid.org.Disclosure Declaration
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
Faculty reports the following relationship(s)
Don Wilson, MD, FNLA
Advisory Board: Alexion
Karen Aspry, MD, FNLA
Contracted Research: Amgen, Akcea, Esperion, Novartis
Speaker: Medscape/WebMD
P. Barton Duell, MD, FNLA
Consultant: Amryt Pharma, Esperion, Regeneron, RegenxBio, Retrophin, Sanofi
Reviewers report the following relationship(s)
Pamela Papp, APRN, CLS, FNLA
Has nothing to disclose.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
CME Questions?
Questions related to this content should be sent to cme@lipid.org.